Gauri Jejurikar

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
BACKGROUND Oral therapy for pulmonary tuberculosis (TB) treatment suffers from the limitation of hepatic metabolism leading insufficient concentration of antitubercular (anti-TB) drugs in alveolar macrophage which harbors Mycobacterium tuberculosis (MTB). Targeted aerosol delivery of antituberculous drug to lung is efficient for treating local lung TB(More)
  • 1